Research explained
Peptide trials: why the placebo group belongs beside the headline
Read peptide trials more clearly: distinguish change from baseline, placebo-group change and the treatment comparison, using STEP 1 as a worked example.
The SlimWithPeps reading room
Evidence and safety
Look closely at study design, peptide blends and product testing.
22 articles · Newest first
Research explained
Are peptides steroids? What the distinction does—and does not—tell you
Peptides and steroids are different chemical categories. Learn why that distinction cannot establish product safety, approval, effectiveness or hormonal effects.
Research explained
Peptide endotoxin testing: what a result below the limit actually means
Learn how to read peptide endotoxin results, reporting limits, units and method suitability—and why a passing result does not establish sterility.
Research explained
Collagen peptides versus whey: which muscle outcome was tested?
Compare collagen and whey muscle research, from six-day protein synthesis measurements to year-long outcomes, without confusing one result for another.
Research explained
Elamipretide, SS-31 and Forzinity: what the FDA approval covers
Understand what Forzinity’s elamipretide approval covers, the limits of its early trials, and what the new confirmatory study is designed to establish.
Research explained
Collagen peptides for joints: pain relief is a different claim from cartilage repair
Compare collagen joint-pain trials, placebo-adjusted results and registry details to understand why symptom relief does not establish cartilage repair.
Research explained
Peptide immunogenicity: what tirzepatide antibody results actually mean
Understand peptide immunogenicity through tirzepatide trial data: antibody detection, clinical effects, safety findings and limits of cross-drug comparisons.
Research explained
Oxytocin clinical research: why improvement is not the same as a treatment effect
Read the oxytocin autism trial results and a 2026 placebo analysis, with clear explanations of treatment effects, formulation differences and limits.
Research explained
PT-141 and Vyleesi: what bremelanotide approval actually covers
Understand Vyleesi’s approved use, the bremelanotide trial outcomes, and why an online PT-141 preparation does not inherit a prescription product’s approval.
Research explained
Kisspeptin human studies: what the new 12-day hormone experiment shows
Explore a 2026 kisspeptin-10 study in healthy men, why timing affected hormone responses, and which fertility and long-term treatment questions remain open.
Research explained
LL-37 peptide research: what the larger wound-healing trial found
Examine the LL-37 venous-ulcer trial, its overall negative finding and exploratory subgroup result, and why topical research does not validate injected products.
Research explained
Epitalon human studies: telomere findings and the longevity gap
Learn what recent epitalon cell research measured, why telomere changes do not prove longer human life, and why epithalamin is a separate substance.
Research explained
Semax human studies: what a stroke-rehabilitation paper can tell us
Read a Semax stroke-rehabilitation study in context: participant groups, BDNF measurements, functional outcomes and limits on cognitive-enhancement claims.
Research explained
Selank human studies: what an anxiety-drug comparison establishes
Examine a Selank anxiety study comparing 62 patients, the difference between similar results and proven equivalence, and the limits of abstract-only evidence.
Research explained
DSIP sleep research: why the small insomnia trials disagree
Compare two small DSIP insomnia studies, their different sleep outcomes, and why a sleep-inducing name does not establish a reliable insomnia treatment.
Research explained
KPV peptide human studies: what the cell and mouse research means
KPV research includes human-derived cells and mouse colitis models. Learn why these are not human treatment trials and which questions remain open.
Research explained
MOTS-c human studies: exercise biology is not an injection trial
Separate human MOTS-c measurements during exercise from mouse treatment experiments, and understand why neither proves an injectable product benefits people.
Research explained
Thymosin alpha-1 clinical trials: reading the corrected TESTS result
Explore the TESTS sepsis trial of thymosin alpha-1, its published correction, and why an overall result differs from an exploratory subgroup claim.
Research explained
TB-500 vs thymosin beta-4: why the exact molecule matters
TB-500 and full-length thymosin beta-4 are not interchangeable research labels. Learn how to check which molecule a human study actually tested.
Blend comparison
GLOW vs KLOW: ingredients, labels and the evidence
Compare the actual GLOW and KLOW labels, understand what KPV adds, and learn why ingredient studies cannot establish a blend’s clinical benefits.
Research literacy
How to read a peptide COA: purity, identity and sterility
Learn what a peptide COA can show about identity, purity, content and microbiological testing—and how to spot the questions a report leaves unanswered.
Evidence check
BPC-157: where the human evidence begins—and ends
Why promising experiments, small human reports and established clinical evidence are different things.